Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(currently amended)** A compound of formula I and pharmaceutically acceptable salts thereof:



I

wherein

A is O, CO, S, NR^d, or CR^bR^c;

D is COR^4, $C(O)NR^dR^4$, $C(O)OR^4$, ~~SO_2R^4, $SO_2NR^dR^4$~~;

X, Y and Z are independently a ring carbon atom or a ring nitrogen atom, with the proviso that 0-3 X, 0-3 Y and 0-3 Z are ring nitrogen atoms;

R^{1a} and R^{1b} are independently selected from (1) H, (2) halogen, (3) C_{1-6}alkyl optionally substituted with 1-5 groups independently selected from halogen, nitro, cyano, COR^a, CO_2R^a, $C(O)NR^dR^e$, OR^a, $OC(O)R^a$, SR^a, SO_2R^f, $S(O)R^f$, NR^dR^e, $NR^dC(O)R^a$ and $NR^dSO_2R^f$, (4) $C(O)R^a$, (5) CO_2R^a, (6) $C(O)NR^dR^e$, (7) OR^a, (8) $OC(O)R^a$, (9) $OC(O)NR^dR^e$, (10) NR^dR^e, (11) $NR^dC(O)R^a$, (12) $NR^dC(O)OR^a$, (13) $NR^dC(O)NR^dR^e$, (14) $NR^dSO_2R^f$, (15) SR^a, (16) $S(O)R^f$, (17) SO_2R^f, (18) $SO_2NR^dR^e$, (19) CN, (20) NO_2, (21) optionally substituted aryl, (22) optionally substituted heteroaryl, (23) optionally substituted heterocyclyl, (24) optionally substituted aryl-C_{1-6}alkyl, (25) optionally substituted heteroaryl-C_{1-6}alkyl, and (26) optionally substituted heterocyclyl-C_{1-6}alkyl; wherein the substituents for aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^a, NR^dR^e, $NR^dC(O)R^a$, $NR^dSO_2R^f$, $OC(O)R^a$, $NR^dC(O)_2R^a$, SR^a,

SO_2R^f, oxo (for heterocyclyl and heterocyclylalkyl), $C(O)R^a$, $C(O)_2R^a$, C_{1-4} alkyloxy, aryl, aryl-C_{1-4}alkyl, heteroaryl, heteroaryl-C_{1-4}alkyl, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms, or

R^{1a}, R^{1b} and adjacent carbon atoms to which they are attached together form a saturated, partially unsaturated or aromatic 5- or 6-membered ring containing 0 to 2 heteroatoms selected from N, N-Rg, O and S;

R^{2a} and R^{3a} are independently selected from (1) H, (2) halogen, (3) OR^a, (4) NR^dR^e, (5) CN, (6) NO_2, (7) CO_2R^a, (8) COR^a, and (9) C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms,

R^4 is selected from (1) C_{1-6}alkyl substituted with 1 to 5 halogen atoms, OR^a, NR^dR^e or $C(O)NR^dR^e$ in which, for these two occurrences, R^d and R^e together complete a 4- to 8-membered ring optionally containing an additional heteroatom selected from NRg, O, S, and SO_2, and said ring being optionally fused to a benzene or a 5- or 6-membered heteraromatic ring, and optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, nitro, ORg, oxo, C_{3-6} cycloalkyl, aryl, heteroaryl, NRgRg, NRgCORg, $NRgCO_2Rg$ and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms; (2) optionally substituted heteroaryl; (3) optionally substituted heteroaryl-C_{1-4}alkyl; (4) optionally substituted heterocyclyl; (4) optionally substituted heterocyclyl-C_{1-4}alkyl; wherein the substituents for heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^a, NR^dR^e, $NR^dC(O)R^a$, $NR^dSO_2R^f$, $OC(O)R^a$, $NR^dC(O)_2R^a$, SR^a, SO_2R^f, oxo (for heterocyclyl and heterocyclylalkyl), $C(O)R^a$, $C(O)_2R^a$, C_{1-4} alkyloxy, aryl, aryl-C_{1-4}alkyl, heteroaryl, heteroaryl-C_{1-4}alkyl, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms~~(1) H, (2) C_{1-6}alkyl optionally substituted with 1 to 5 groups independently selected from halogen, nitro, cyano, C_{3-6}cycloalkyl, COR^a, CO_2R^a, $C(O)NR^dR^e$, OR^a, $OC(O)R^a$, SR^a, SO_2R^f, $S(O)R^f$, NR^dR^e, $NR^dC(O)R^a$, $NR^dSO_2R^f$, and $NR^dC(O)_2R^a$, (3) optionally substituted C_{3-6}cycloalkyl, (4) COR^a, (5) $COOR^a$, (6) optionally substituted aryl, (7) optionally substituted heteroaryl, (8) optionally substituted heterocyclyl, (9) optionally substituted aryl-C_{1-6}alkyl, (10) optionally substituted heteroaryl-C_{1-6}alkyl, and (11) optionally substituted heterocyclyl-C_{1-6}alkyl; wherein the substituents for cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^a, NR^dR^e, $NR^dC(O)R^a$, $NR^dSO_2R^f$, $OC(O)R^a$, $NR^dC(O)_2R^a$, SR^a, SO_2R^f, oxo (for heterocyclyl and heterocyclylalkyl), $C(O)R^a$, $C(O)_2R^a$, C_{1-4} alkyloxy, aryl~~

~~optionally substituted with 1 or 2 halogen atoms, aryl-C_{1-4}alkyl, heteroaryl, heteroaryl-C_{1-4}alkyl, C_{3-6}-cycloalkyl and C_{1-4}-alkyl optionally substituted with 1 to 5 halogen atoms;~~

~~$R^{4'}$ is a group selected from R^4 except $R^{4'}$ is not H;~~

R^a is (1) H, (2) C_{1-6} alkyl optionally substituted with 1 to 5 groups independently selected from halogen, cyano, nitro, OH, C_{1-4} alkyloxy and C_{3-6} cycloalkyl, (3) C_{3-6} cycloalkyl, (4) optionally substituted aryl, (5) optionally substituted heteroaryl, (6) optionally substituted heterocyclyl, (7) optionally substituted aryl-C_{1-6}alkyl, (8) optionally substituted heteroaryl-C_{1-6}alkyl, and (9) optionally substituted heterocyclyl-C_{1-6}alkyl; wherein the substituents for aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^g, NR^dR^e, $NR^dC(O)R^g$, $NR^dSO_2R^f$, $OC(O)R^g$, $NR^dC(O)_2R^g$, SR^g, SO_2R^f, oxo (for heterocyclyl and heterocyclylalkyl), $C(O)R^{g^a}$, $C(O)_2R^g$, C_{1-4} alkyloxy, aryl, aryl-C_{1-4}alkyl, heteroaryl, heteroaryl-C_{1-4}alkyl, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms;

R^b and R^c are independently selected from H, halogen, or C_{1-4}alkyl optionally substituted with 1 to 5 halogen atoms;

R^d and R^e are independently selected from (1) H, (2) C_{1-4}alkyl, optionally substituted with 1 to 5 groups independently selected from halogen, amino, mono-C_{1-4}alkylamino, di-C_{1-4}alkylamino, and SO_2R^f, (3) aryl-C_{1-6}alkyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C_{1-4} alkyloxy, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms, (4) heteroaryl-C_{1-6}alkyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C_{1-4} alkyloxy, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms,and (5) C_{3-6} cycloalkyl, or R^d and R^e, or R^d and R^4~~, or R^d and $R^{4'}$~~, together with the atom or atoms to which they are attached, complete a 4- to 8-membered saturated, partially saturated or aromatic ring optionally containing 1 to 3 heteroatoms independently selected from N, NRg, O, S, and SO_2, and said ring being optionally fused to a benzene or a 5- or 6-membered heteraromatic ring, and optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, nitro, ORg, oxo, C_{3-6} cycloalkyl, aryl, aryl-C_{1-4}alkyl, heteroaryl, NRgRg, NRgCORg, $NR^gCO_2R^g$ and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms;

R^f is selected from (1) C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms, (2) C_{1-4} alkyloxy, and (3) aryl optionally substituted with 1 to 3 groups selected from halogen, cyano,

nitro, OH, C_{1-4} alkyloxy, C_{3-6} cycloalkyl and C_{1-4} alkyl optionally substituted with 1 to 5 halogen atoms;

Rg is selected from (1) H, (2) C_{1-4}alkyl, (3) aryl, (4) aryl-C_{1-6}alkyl, (5) $C(O)_2C_{1-4}$alkyl and (6) $C(O)C_{1-4}$alkyl;

~~with the proviso that when each occurrence of X, Y and Z is a ring carbon atom, R^{1a} and R^{1b} are each hydrogen or chlorine, and R^{2a} and R^{2b} are each hydrogen, then D is not $NHC(O)C_{1-6}$alkyl;~~

~~with the further proviso that the following compound is excluded:~~



2. **(original)** A compound of Claim 1 wherein A is C(O) or O.

3. **(canceled)**

4. **(original)** A compound of Claim 1 wherein each occurrence of Y and Z represents a ring carbon atom, and one X is a ring carbon or nitrogen atom and the others are ring carbon atoms.

5. **(canceled)**

6. **(currently amended)** A compound of Claim 1 having the formula Ia(1) and pharmaceutically acceptable salts thereof:





~~I~~a(1)

wherein

A is O or C(O);

one of X is a ring carbon or nitrogen atom, and the others are ring carbon atoms;

~~D is $C(O)R^4$, $C(O)NR^dR^4$ or $C(O)OR^4$;~~

R^{1a} and R^{1b} are independently selected from hydrogen, halogen, C_{1-4}alkyl, cyano, SR^a, OR^a and CF_3;

R^{2a} and R^{3a} are independently H or halogen;

R^4 is selected from (1) C_{1-4}alkyl substituted with one to 5 groups independently selected from halogen, C_{3-6} cycloalkyl, NR^dR^e, $NR^dC(O)_2R^a$, $C(O)NR^dR^e$, $C(O)OR^a$, and OR^a; (2) C_{3-6}cycloalkyl; (3) phenyl; (4) phenyl-C_{1-4}alkyl; (5) optionally substituted heteroaryl; (6) optionally substituted heteroaryl-C_{1-4}alkyl; (7) optionally substituted heterocyclyl; and (8) optionally substituted heterocyclyl-C_{1-4}alkyl; wherein heteroaryl, including as part of heteroarylalkyl, is selected from benzofuranyl, pyrazolo[1,5-a]pyrimidinyl, 1-azaindolizinyl, s-triazolo[1,5-a]pyrimidinyl, thieno[3,2-b]pyridinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyrimidinyl, benzisoxazolyl, pyridyl, indolyl, benzimidazolyl, benzthiazolyl and imidazo[2,1-b]thiazolyl; heterocyclyl, including as part of heterocyclylalkyl, is selected from morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl and imidazolidinyl; the substituents for heteroaryl is 1 or 2 groups independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, and OR^a; and the substituents for heterocyclyl is 1 to 3 groups independently selected from oxo and C_{1-4}alkyl,

R^a and R^d are as defined in Claim 1.

7. **(canceled)**

8. **(currently amended)** A compound of Claim ~~7~~ 6 wherein R^4 is selected from (1) C_{1-4}alkyl substituted with NR^dR^e or $C(O)NR^dR^e$ where for both groups R^d and R^e, together with the nitrogen atom to which they are attached, complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NRg, O, S and SO_2, and wherein said substituent is 1 or 2 groups independently selected from OR^a, halogen, C_{1-4}alkyl and oxo; (2) optionally substituted heteroaryl wherein said heteroaryl is selected from pyrazolyl, isoxazolyl, pyrimidinyl, benzofuranyl, pyrazolo[1,5-a]pyrimidinyl, 1-azaindolizinyl, s-triazolo[1,5-a]pyrimidinyl, imidazo[2,1-b]thiazolyl, thieno[3,2-b]pyridinyl, and said substituent is 1 to 3 groups independently selected from furanyl, pyridyl, benzyl, phenyl optionally substituted with halogen, C_{1-4}alkyl, C3-6cycloalkyl, trifluoromethyl, halogen, and C_{1-4}alkoxy.

9. **(currently amended)** A compound of Claim ~~6~~ 1 having the formula Ia(2) and pharmaceutically acceptable salts thereof:



Ia(2)

~~wherein D is C(O)NR^{d}R^4,~~ wherein R^d is H and R^4 is selected from (1) C_{1-4}alkyl substituted with a group selected from halogen, OR^a, CO_2R^a, $NHCOR^a$, NR^dR^e and $C(O)NR^dR^e$; (2) optionally substituted heteroaryl-C_{1-4}alkyl wherein heteroaryl is selected from azaindolizinyl, ~~imidazoly~~imidazolyl, benzimidazolyl, pyrazinyl, pyridyl, indolyl, triazolyl, thiazolyl, imidazo[1,2-a]pyridyl, imidazo[1,2-a]pyrimidinyl, imidazo[2,1-b]thiazolyl, and pyrazolo[1,5-a]-pyrimidinyl; (3) optionally substituted heterocycylyl-C_{1-4}alkyl wherein heterocyclyl is selected from tetrahydropyranyl, tetrahydrofuranyl and dioxanyl; (4) optionally substituted heterocyclyl selected from pyrrolidinyl and piperidinyl; (5) CO_2R^a; (6) C_{3-6}cycloalkyl; and (7) optionally substitued phenyl-C_{1-4}alkyl; or R^d and R^4 together with the nitrogen atom to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected fom NRg, O, S and SO_2, wherein said ring is optionally

fused to a benzene or a 5- or 6-membered heteroaryl ring, and said substituent is 1 or 2 groups independently selected from OR^a, halogen, C_{1-4}alkyl, NR^dR^e, NR^dCO2R^a, and oxo.

10. **(original)** A compound of Claim 9 wherein R^d is H and R^4 is selected from (1) C_{1-4}alkyl substituted with NR^dR^e or $C(O)NR^dR^e$, wherein for both groups R^d and R^e together with the nitrogen to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NRg, O, S and SO_2, and wherein said substituent is 1 or 2 groups independently selected from OR^a, halogen, C_{1-4}alkyl and oxo; (2) heterocyclyl or heterocyclyl-C_{1-4}alkyl wherein said heterocyclyl is selected from pyrrolidinyl, 1,4-dioxanyl, and tetrahydropyranyl; and (3) heteroaryl-C_{1-4}alkyl optionally substituted with 1 to 3 C_{1-4}alkyl groups, wherein said heteroaryl is selected from imidazolyl, 1-azaindolizinyl, imidazo[2,1-b]thiazolyl, and pyrimidinyl.

11. **(currently amended)** A compound of Claim ~~7~~ 1 having the formula Ia(3) an pharmaceutically acceptable salts thereof:



Ia(3)

wherein ~~D is C(O)OR4, and~~ R^4 is selected from (1) C_{2-4}alkyl substituted with NR^dR^e or $C(O)NR^dR^e$ in which, for these two groups, R^d and R^e together with the nitrogen atom to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NRg, O, S and SO_2, and wherein said substituent is 1 or 2 groups independently selected from OR^a, halogen, C_{1-4}alkyl and oxo; (2) heterocyclyl-C_{1-4}alkyl optionally substituted with 1 to 3 groups independently selected from C_{1-4}alkyl and oxo, wherein heterocyclyl is selected from tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, oxazolidinyl, dioxanyl, and dioxolanyl; (3) furanyl-C_{1-4}alkyl; and (4) phenyl-C_{1-4}alkyl.

12. **(canceled)**

13. **(original)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

14. **(currently amended)** ~~Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament useful in~~ A method for the treatment ~~or prevention~~ of diseases or disorders mediated through the bradykinin receptor pathway which comprises administering to a patient in need thereof a compound of formula I or a pharmaceutically acceptable salt thereof.

15. **(currently amended)** The ~~use~~ method of Claim 14 wherein said disease or disorder is selected from neuropathic pain, acute pain and inflammatory pain.